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Combination therapy with pegylated interferon and ribavirin is considered the new standard
therapy for naïve patients with chronic hepatitis C. We evaluated the efficacy and safety of treatment
with weight-based peginterferon α-2b (1.5 mg/kg per week) plus ribavirin (800-1,200 mg/day) for 48
weeks in naïve, relapser and non-responder (to previous treatment with interferon plus ribavirin)
patients with chronic hepatitis C. Sixty-seven naïve, 26 relapser and 40 non-responder patients were
enrolled. The overall sustained virological response (SVR) for the intention-to-treat population was
54% for naïve, 62% for relapser and 38% for non-responder patients. In the naïve subgroup, SVR was
significantly higher in patients with the non-1 genotype (67%) compared to those with genotype 1
(45%). In relapsers and non-responders, SVR was, respectively, 69% and 24% in patients with genotype
1 and 43% and 73% in those with genotype non-1. There were no significant differences in SVR rates
among the three body weight ranges (< 65 kg, 65-85 kg and > 85 kg) in any of the subgroups. Early
virological response (EVR) was reached by 78%, 81% and 58% of naïve, relapser and non-responder
patients, respectively, and among those with EVR, 63%, 67% and 61%, respectively, subsequently
achieved SVR. All of the non-responder patients who did not have EVR reached SVR. Treatment was
discontinued in 13% of the patients, due to loss to follow-up, hematological abnormalities or
depression.
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Chronic hepatitis C promotes a slow but progressive
deterioration of liver function in up to 70% of affected
individuals [1]. Treatment for hepatitis C has evolved from
the use of interferon-a monotherapy to combination therapy
with interferon plus ribavirin [2-5], and more recently to
combination therapy with pegylated interferon α-2b or α-2a
once a week. These regimens have given a significantly higher
sustained-virological-response (SVR) rate than combination
therapy with interferon and ribavirin in the treatment of naïve
patients (54%-56 % vs. 44%-47%) [6,7]; they are considered
the new standard therapy for this group of patients [8]. Despite
similar SVR rates observed with the two pegylated interferons,
the use of these two drugs differs significantly, since
peginterferon α-2a is given in fixed doses, while peginterferon
α-2b is dosed according to the patient’s weight, based on
previous findings that response rates to interferon α-2b
monotherapy were strongly influenced by body weight [9].
We evaluated the efficacy and safety of weight-based
peginterferon α-2b and ribavirin treatment of Brazilian patients
with chronic hepatitis C. Since the efficacy of peginterferon in
the retreatment of patients who have not achieved SVR with
interferon plus ribavirin is not well established, we included
patients that had been non-responders or who had relapsed
in response to previous interferon plus ribavirin therapy, along
with naïve patients.
Material and Methods
Study design
This was an open, prospective, national, multicenter study,
approved by the institutional ethics committee of all seven
participating centers; all patients provided signed informed
consent. Patients who met the inclusion criteria received a
combination of peginterferon α-2b plus ribavirin for 48 weeks.
Peginterferon α-2b (PegIntron, Schering Plough, Kenilworth,
NJ, USA) was used at a dose of 1.5 mg/kg per week
subcutaneously in a single injection. Ribavirin (Rebetol,
Schering Plough, Kenilworth, NJ, USA) was given orally twice
a day at a total daily dose of 800 mg (naïve patients: body
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weight < 65 kg), 1,000 mg (naïve patients: body weight 65-85
kg; relapsers and non-responders: < 75 kg) or 1,200 mg (naïve
patients: body weight > 85 kg; relapsers and non-responders
> 75 kg).
Stepwise reductions in peginterferon α-2b dosages to 1.0
mg/kg per week were made whenever platelets fell below
80,000/mm3 or granulocytes fell below 750 cells/mm3.
Reductions in ribavirin dosages to half of initial doses were
made whenever hemoglobin levels fell below 10 mg/dL. Full
doses were restarted after normalization of the event.
All patients were evaluated for safety and tolerance at the
end of weeks 2, 4, 8, 12, and every 6 weeks during treatment.
Biochemical (ALT, AST, glycemia, creatinine, bilirubin, GGT,
alkaline phosphatase, total protein, albumin) and hematology
exams (complete blood count, platelet count) tests were made
at every visit. Thyroid function (TSH and free T4) was
assessed at baseline and at weeks 8 and 24. Serum HCV-RNA
levels were quantitatively assessed by RT- PCR assay (Cobas
Amplicor HCV test, version 2.0; lower limit of detection, 100
copies [50 IU] per mm3) at baseline and at week 12, while
qualitative RT-PCR was done at week 48 (end of treatment)
and at follow-up (24 weeks after the end of treatment).
EVR was defined as either undetectable serum HCV-RNA
or a S 2-log decline in serum HCV-RNA, based on quantitative
RT-PCR assays, by week 12 of treatment. SVR was defined as
absence of detectable HCV-RNA at the end of follow-up (24
weeks after the end of treatment) by qualitative RT-PCR assay.
Patient selection
Eligible subjects were previously untreated (naïve) patients
(15-65 years old), previously treated with interferon and
ribavirin who presented detectable HCV RNA measured during
or following treatment after a period of undetectable HCV
RNA (relapsing patients) and those previously treated with
interferon and ribavirin who continued viremic throughout
treatment and follow-up (non-responder patients). All patients
had detectable HCV-RNA in the serum, abnormal serum ALT
concentrations for at least six months before the beginning of
the protocol, and a liver biopsy specimen collected within 18
months of entry in the study, with histopathological
confirmation of chronic hepatitis C. Histological activity of 81
out of 133 cases (61%) was revised by a center pathologist
using the METAVIR Scoring System: 39 out of 67 naïve
patients (58%), 23 out of 40 non-responders (58%) and 19 out
of 26 (73%) relapsers. Fibrosis of each liver biopsy specimen
was staged on a scale of 0 to 4 (0, no fibrosis; 1, portal fibrosis
without septa formation; 2, few septa; 3, numerous septa
without cirrhosis; 4, cirrhosis). The activity, measured as the
intensity of necroinflammatory lesions, was scored as follows:
A0, no histological activity; A1, mild activity; A2, moderate
activity; and A3, severe activity) [10, 11].
Patients were excluded from the study if they had
hemoglobin values < 12 g/dL, neutrophils < 1,500/mm3, platelets
< 100,000/ mm3, human immunodeficiency virus (HIV) infection,
coinfection with hepatitis B, decompensated liver disease,
seizure disorders, previous organ transplantation, significant
cardiovascular dysfunction, chronic pulmonary disease,
poorly controlled diabetes, other cause of liver disease, pre-
existing psychiatric disease, hemoglobinopathies, hemophilia,
clinically significant retinal abnormalities or immunologically-
mediated disease. Laboratory values for serum bilirubin,
prothrombin time, albumin, glycemia, creatinine and alpha-
fetoprotein had to be within the normal range. All patients
had an ultrasonography evaluation at least three months
before entry in the study with no evidence of nodules or
hepatocarcinoma. Patients were also excluded if they were
consuming alcohol or using intravenous or inhaled drugs on
a regular basis, were pregnant or nursing. Non-responders
and relapsers must have finished previous interferon plus
ribavirin treatment at least six months previously.
Endpoints
The primary endpoint for this study was SVR, defined as
undetectable HCV-RNA in the serum 24 weeks after the end of
treatment. EVR and safety were secondary endpoints. Results
were recorded for the intention-to-treatment (ITT) population
(all patients who received at least one dose of the study
medication) as well as for the on-treatment population.
Statistical analysis
Contingency tables were used for comparing the
distribution of SVR across factor levels (genotype, viral load,
body weight and degree of fibrosis). The chi-square test was
employed for evaluating statistical differences with P < 0.05.
Results
Baseline characteristics
From March 2001 to December 2002, 133 patients were
enrolled and received at least one dose of the medication;
they were comprised of 67 naïve, 26 relapser and 40 non-
responder patients. Baseline host and viral characteristics are
shown in Table 1. Most of the patients were male (67%), with
a mean age of 44 ± 0.85 years and a mean body mass index of
26.5 ± 0.34 kg/m2. HCV genotype 1 was the most frequent in
this series (66%). and HCV-RNA was > 800,000 copies/mL in
39% of the patients.
Efficacy of therapy
Of the 133 included patients, 116 completed therapy (59
naïve, 23 relapser and 34 non-responder patients) and were
considered in the on-treatment analysis. SVR results for the
intention-to-treat population and the on-treatment population
are shown in Table 2. The overall SVR was 54% for naïve
patients, 62% for relapsers and 38% for non-responders in
the intention-to-treat population and 61%, 70% and 44%,
respectively, for the on-treatment population. In the naïve
subgroup, SVR was significantly higher in patients with
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Table 1. Baseline characteristics of chronic hepatitis C patients
Table 2. Treatment response by week 12 (early virological response [EVR]), end of treatment and end of follow-up (sustained
virological response [SVR]): intention-to-treat (ITT) and on-treatment analysis of chronic hepatitis C patients
 Peginterferon α-2b and Ribavirin in Chronic Hepatitis C
Naïve (n=67) Relapser (n=26) Non-responder (n=40)
Sex (% Male) 64% 62% 75%
Age (years, mean± SD [Range]) 43.3±0.96 (24.0-61.0) 45.5±2.64 (20.0-68.0) 44.3±1.61 (15.0-65.0)
Body weight (kg, mean± SD [Range]) 77.0±1.69 (52.0-112.0) 75.0±2.92 (45.2-102.0) 75.3±1.98 (46.8-101.0)
BMI (kg/m2, mean± SD [Range]) 26.7±0.47 (20.6-37.6) 25.7±0.79 (18.8-33.1) 26.6±0.63 (20.0-36.0)
Genotype 1 60% 73% 73%
High viral load (> 800,000 copies/mL) 40% 31% 43%
Degree of fibrosis* (Available in 39 cases) (Available in 19 cases) (Available in 23 cases)
F0-F2 64% 74% 74%
F3 26% 21% 13%
F4 10% 5% 13%
HCV-RNA (copies/mL, mean± SEM) 910,425 ± 157,820 660,833 ± 114,108 1,018,131 ± 197,534
ALT  (mean ± SEM) 146.2 ±13.3 83.3 ± 6.5 130.6 ± 15.7
Normal limits:
Female: 10-36 U/L
Male: 10-44 U/L
SD: Standard deviation; BMI: Body mass index; SEM: Standard error of the media. * Available in 81 out of 133 cases (61%).
Treatment response Naïve Relapsers Non-responders
 ITT On-treatment ITT On-treatment ITT On-treatment
Overall
12 weeks (EVR) 78% (52/67)• 88% (52/59) 81% (21/26)¶ 91% (21/23) 58% (23/40)£ 68% (23/34)
End of treatment 67% (45/67) 76% (45/59) 73% (19/26) 83% (19/23) 45% (18/40) 53% (18/34)
End of follow-up (SVR) 54% (36/67) 61% (36/59) 62% (16/26) 70% (16/23) 38% (15/40) 44% (15/34)
SVR by genotype#
1 45% (18/40) 49% (18/37) 69%(13/19) 72% (13/18) 24% (7/29) 28% (7/25)
Non-1 67% (18/27) 82% (18/22) 43%(3/07) 60% (3/5) 73% (8/11) 89% (8/9)
SVR by baseline HCV§
< 800,000 copies/mL 58% (23/40) 66% (23/35) 56%(10/18) 63% (10/16) 40% (9/23) 43% (9/21)
> 800,000 copies/mL 48% (13/27) 54% (13/24) 75%(6/8) 88% (6/7) 35% (6/17) 46% (6/13)
SVR by body weight *
< 65 kg 57% (8/14) 67% (8/12) 78% (7/9) 78% (7/9) 25% (2/8) 29% (2/7)
65 – 85 kg 49% (17/35) 55% (17/31) 71% (5/7) 71% (5/7) 42% (10/24) 48% (10/21)
> 85 kg 61% (11/18) 69% (11/16) 40% (4/10) 57% (4/7) 38% (3/8) 50% (3/6)
SVR by degree of fibrosis&
F0-F2 60% (15/25) 68% (15/22) 57% (8/14) 67% (8/12) 38% (6/16) 40% (6/15)
F3-F4 29% (4/14) 40% (4/10) 80% (4/5) 80% (4/5) 43% (3/7) 75% (3/4)
•  Two patients did not have an HCV-RNA exam at week 12 and one patient dropped out at week 2.
¶ One patient dropped out at week 2.
£ One patient did not have an HCV-RNA exam at week 12 and three patients dropped out at week 8.
# SVR rate was significantly higher in genotype non-1 compared to genotype 1 only in the naïve subgroup.
§ There were no significant differences in SVR rates between high and low viral load in each subgroup.
* There were no significant differences in SVR rates among the three body weight ranges in each subgroup.
& There were no significant differences in SVR rates between F0-F2 and F3-F4 in each subgroup.
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genotype non-1 (67%) compared to patients with genotype 1
(45%) (P<0.05). In relapsers and non-responders, SVR was,
respectively, 69% and 24% in patients with genotype 1 and
43% and 73% in those with genotype non-1.
Among naïve, relapser and non-responder patients with
high baseline viral load, 48%, 75% and 35%, respectively,
reached SVR, while in patients with low baseline viral load,
58%, 56% and 40%, respectively, achieved SVR. As shown in
Table 2, there were no significant differences in SVR rates
among the three body weight ranges (< 65 kg, 65-85 kg and >
85 kg) in any of the subgroups. Among naïve, relapser and
non-responder patients with an F0-F2 fibrosis score, 60%,
57% and 38%, respectively, had SVR, while in patients with an
F3-F4 fibrosis score, 29%, 80% and 43%, respectively, achieved
SVR. The biochemical (alanine aminotransferase) response
rates at the end of treatment and at the end of follow up were,
respectively, 79% and 74% for naïve patients, 90% and 86%
for relapsers and 66% and 45% for non-responders. Nearly all
naïve patients and relapsers who achieved SVR also had
normal ALT values at the end of follow up: 97% and 93%,
respectively, while normal ALT values were observed in 80%
of non-responders who reached SVR.
EVR was reached by 78%, 81% and 58% of naïve, relapser
and non-responder patients, respectively, and among those
with EVR, 63%, 67% and 61% subsequently achieved SVR.
Among the 12 naïve patients who did not have EVR, 10
patients completed therapy and four reached SVR. Among
the four relapser patients who did not present EVR, three
patients completed therapy and two achieved SVR. Among
the 13 non-responder patients who did not have EVR, 12
patients completed therapy and none (0%) reached SVR.
Safety
Treatment was discontinued in 17 patients (13%) due to
abnormalities in the laboratory tests or other adverse events:
12% of the naïve patients, 11% of relapsers and 15% of non-
responders. The reasons for treatment discontinuation were
loss of follow-up (7/17) depression (6/17), neutropenia (2/17),
anemia (1/17) and low platelet counts (1/17). The percentage
of patients reporting the most common adverse events (fever,
myalgia, headache, fatigue, nausea, rigors and decreased
appetite) decreased with time. Alopecia was more frequently
reported after treatment week 18. The number of patients
reporting irritability, insomnia and depression was low and
remained constant throughout the entire treatment period.
Hemoglobin concentrations fell after week 2, stabilized
after week 12 and returned to baseline values during follow-
up. Granulocyte counts decreased after week 2, stabilized after
week 8 and returned to baseline values during follow-up.
Platelet counts reached the lowest values on week 8; then
they gradually increased and normalized during follow-up
(Figure 1). The temporal pattern of decrease of hematological
variables did not differ among the subgroups of naïve, relapser
and non-responder patients. Decreases in hematological
variables, requiring reduction of ribavirin and/or peginterferon
α-2b doses, were observed as follows for naïve, relapsers and
non-responder patients, respectively: hemoglobin below 10
mg/dL, 10%, 11.5% and 22%; granulocytes below 750 cells/
mL, 22%, 19% and 20%, and platelets below 80,000 cells/mL,
4%, 4% and 17%.
Body weight decreased progressively throughout the
treatment period and stabilized after week 30 (Figure 1). Mean
body weight loss at the end of therapy was 8%. A significant
increase in ALT concentration (greater than five times
baseline) was observed in only one patient (from the relapser
group) during the study.
Discussion
In this study carried out in a Brazilian population, with the
administration of weight-based peginterferon α-2b at a dose
of 1.5 mg/kg per week plus ribavirin for 48 weeks, the success
rates observed for naïve patients were similar to those
observed by Manns et al. [6], with an overall SVR rate of 54%
in the intention-to-treat population and 61% in the on-
treatment population. The SVR rates in the population infected
with genotype 1 (45% in the intention-to-treat analysis and
49% in the on-treatment analysis) were also similar to those
described by Manns et al. Liver histology was reviewed by
the same pathologist in 58% of the naive patients; the
evaluation of this subgroup showed a SVR rate of 60% in the
intention-to-treat analysis and 68% in the on-treatment
analysis, in patients with fibrosis grade 0 to 2, and a SVR rate
of 29% in the intention-to-treat analysis and 40% in the on-
treatment analysis in patients with fibrosis grades 3 and 4.
The lack of significant differences in SVR rates between
patients with minimal versus advanced fibrosis degree as well
as between patients with low versus high viral load could be
due to the small sample size.
The SVR results in relapsers who had previously received
interferon plus ribavirin therapy confirmed the conclusions
of a previous study that stated that these patients are an ideal
subgroup of patients for retreatment [12], since an overall
SVR rate of 62% in the intention-to-treat analysis and 70% in
the on-treatment analysis was observed. These results were
similar to those reported by Portal et al. in a study of 46
relapsers who received peginterferon α-2b at a dose of 0.7
mg/kg per week plus ribavirin (800-1,000 mg/day) for 48 weeks
or peginterferon α-2b at a dose of 1.5 mg/kg per week for eight
weeks, followed by peginterferon α-2b at a dose of 0.7 mg/kg
for 40 weeks plus ribavirin (800-1,000 mg/day) for 48 weeks.
The SVR rates did not differ between the two treatment groups,
with an overall SVR of 68% [13]. High SVR rates were observed
in patients with genotype 1 both in our sample (69% in the
intention-to-treat population) and in the population studied
by Portal et al. (69% and 73%). In the EPIC3 trial, Poynard et
al. reported an overall SVR of 39% in relapsers receiving
peginterferon α-2b at a dose of 1.5 mg/kg per week plus
ribavirin (800-1,400 mg/day) for 48 weeks. Among patients
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with genotype 1, only 29% reached SVR [14]. Differences in
the characteristics of these populations might explain the
differences found in the SVR rates between the studies. We
found that 69% of the relapsers in our sample had a low viral
load, which could partially explain the high SVR rates.
SVR rates attained by non-responders (38% in the
intention-to-treat analysis and 44% in the on-treatment
analysis), although much lower than those reported for the
group of relapsers, were higher than those observed in other
studies that included non-responders to prior interferon plus
ribavirin therapy. In the EPIC3 trial, an overall SVR of 15% was
observed in non-responders receiving peginterferon α-2b at
a dose of 1.5 mg/kg per week plus ribavirin (800-1,400 mg/day)
for 48 weeks [14]. Shiffman et al. treated 385 previous non-
responders to interferon plus ribavirin with peginterferon α-
2a at a dose of 180 mg per week, along with ribavirin (1,000-
1,200 mg/d), and observed an overall SVR rate of 12% [15].
When compared to our population, the population studied
by Shiffman had a higher percentage of genotype 1 carriers
(89 vs. 73%) and of patients with high viral load (75 vs. 43%),
in addition to a higher mean body weight (89 vs. 75 kg), which
could in part explain the large difference in the SVR rate
observed in these two studies. The 17% rate of relapse
observed in the non-responders in our study was similar to
the rate observed for the naïve subgroup (20%) and lower
than that reported by Shiffman (50%), which the author
suggests to be the result of the high degree of ribavirin dose
reduction (nearly 40%) [15]. Whether the low rate of ribavirin
dose reduction in the non-responder patients in our study
(22%) contributed to the low rate of relapse remains to be
investigated. Despite the small sample size, we found a high
SVR rate in non-responder patients with genotypes 2 and 3 in
our study (73% in the intention-to-treat analysis).
Analyses of the results of clinical trials with interferon a-
2b monotherapy have shown that SVR rates are strongly
influenced by body weight, since greater body weights were
associated with lower SVR [9]. The impact of body weight on
SVR was also reported by a peginterferon α-2a monotherapy
study [16] and by a peginterferon α-2a plus ribavirin study, in
which a body weight ≤ 75 kg was shown to independently
and significantly increase the odds of achieving SVR [7]. With
the use of weight-based peginterferon α-2b plus ribavirin in
our study, no significant differences were observed in SVR
rates for the three different body weight ranges, i.e., < 65 kg,
65-85 kg and > 85 kg in any of the subgroups. In addition to
allowing patients with higher body weight to reach SVR rates
similar to those achieved by patients with lower body weight,
the administration of weight-based peginterferon α-2b allows
dose adjustment, as body weight decreases during the
treatment, which could have a direct impact on the frequency
of adverse events and, consequently, on the compliance of
patients with significant weight loss secondary to treatment.
PCR analysis at week 12 showed that the percentage of
patients with EVR was similar for naïve patients (78%) and
relapsers (81%), as was as the percentage of patients with
EVR who achieved SVR (63% e 67%, respectively). Differently
from the report by Davis et al. for a phase III peginterferon α-
2b plus ribavirin clinical trial, in which any patient who did not
reach EVR achieved SVR [17], four out of 10 naïve patients
and two out of three relapsers who did not have EVR achieved
SVR. In spite of the lower EVR rate observed in non-responders
(58%), 61% of these patients reached SVR. All of the non-
responders who did not have EVR reached SVR, which
corroborates previous findings that the performance of
quantitative PCR after 12 weeks of therapy with pegylated
interferon is also valuable for maintenance of therapy in non-
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Figure 1. Mean hemoglobin, granulocyte and platelet counts, and mean body weight loss during and after treatment in the three
subgroups.
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responders receiving combination therapy with peginterferon
plus ribavirin [15].
The rate of the most common adverse events (flu-like
symptoms) decreased over time, whereas the rate of depression
and irritability remained relatively steady during the 48 weeks
of treatment. The adverse event that promoted the highest
discontinuation rate was depression. Decreases in hemoglobin
and platelet count values requiring ribavirin and peginterferon
a-2b dose reductions were similar to those previously reported
for naïve patients [6] in the subgroups of naïve and relapser
patients, whereas in the subgroup of non-responders,
decreases in hemoglobin and platelet count values requiring
dose reduction were more frequent. The percentage of patients
with granulocyte count decrease requiring peginterferon α-
2b dose reduction was similar in the three subgroups of
patients.
In conclusion, SVR rates observed after weight-based
combination therapy with peginterferon α-2b plus ribavirin in
naïve Brazilian patients with chronic hepatitis C were similar
to those obtained in the pivotal multicentric phase III study
[6]. Brazilian relapsers who had received prior therapy with
interferon plus ribavirin had a high SVR rate and behaved
similarly to the group of naïve patients in terms of the
prediction value of EVR and of the frequency of abnormal
hematological variables. Non-responders had a higher SVR
rate than those reported in other studies that included non-
responders to prior therapy with interferon plus ribavirin; this
could be at least partly explained by differences in the baseline
characteristics of the study populations; however, these
results need confirmation in a larger-scale study. In agreement
with a previous report [15], PCR carried out on week 12 seems
to be important in non-responders, since the chances of
reaching SVR in patients who did not have EVR are minimal.
This is an important finding, not only because of the savings
it might entail, but also to decrease the exposure of patients,
with fewer chances of adverse events, especially if other
studies confirm the findings that this group of patients is
more prone to greater hemoglobin and platelet count decreases
than the group consisting of naïve and relapser patients.
Further SVR analysis stratified by body weight might be
performed to check our conclusion that administration of
weight-based peginterferon α-2b and ribavirin overcomes the
impact of body weight on SVR rates.
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